Changes in signal transduction pathway induced by gefitinib.

Slides:

Advertisements

Similar presentations

From: IGF-1 Regulates the Extracellular Level of Active MMP-2 and Promotes Müller Glial Cell Motility Invest. Ophthalmol. Vis. Sci ;56(11):

Advertisements

Inhibition of FGFR fusion kinase activity repressed tumor growth in a mouse xenograft model. Inhibition of FGFR fusion kinase activity repressed tumor.

DNA damage induces complex signal activation dynamics across many signaling pathways. DNA damage induces complex signal activation dynamics across many.

Luminex phosphorylation measurements are reproducible and have broad dynamic range Individual difference in insulin‐induced phosphorylation of ERK measured.

The EGF receptor confers BRAF inhibitor resistance in BRAF-mutant melanoma cells. The EGF receptor confers BRAF inhibitor resistance in BRAF-mutant melanoma.

Interfering with HMGA2 expression blocks transformation in metastatic lung cancer cells. Interfering with HMGA2 expression blocks transformation in metastatic.

Signaling induced by BRAF L597R and L597S is sensitive to BRAF and MEK inhibitors. Signaling induced by BRAF L597R and L597S is sensitive to BRAF and MEK.

p38 MAPK activation is required for phosphorylation of Akt at Ser473.

Overexpression of HGF decreases MET protein levels.

AMPK induces VEGF-A production by upregulating ERK signaling.

The role of SRC-C3G-RAP1 signaling in transformation induced by CRKL

Mechanism of piperlongumine induced Sp downregulation.

Thiocolchicoside inhibits TNF-dependent IκBα phosphorylation, IκBα degradation, p65 phosphorylation, and p65 nuclear translocation. Thiocolchicoside inhibits.

Figure 4 DNM1 mutations affect protein levels and self-dimerization (A) HeLa cells were transfected with green fluorescent protein (GFP)-tagged mutant.

IL-6 inhibits insulin-induced formation of p85/IRS-1 complexes.

The p53 pathway is involved in the inhibition of cell proliferation observed in 15-LOX-1-overexpressing cells. The p53 pathway is involved in the inhibition.

Phosphorylation of AMPK-Thr172 before and after metformin treatment in muscle from subjects with type 2 diabetes. Phosphorylation of AMPK-Thr172 before.

Kinetics of BDNF-induced Erk, Akt and PLCγ activation in the presence of 15 mM NaCl or 15 mM KCl. Representative western blots (A) and quantitative plots.

BEZ235 induces MAPK signaling in a FOXO3A-dependent manner.

Aβ-mediated Ras-MAPK signaling and Cyclin D1 expression in B103 cells are dependent on APP expression and can be reversed with MEK or Ras inhibition. Aβ-mediated.

eNOS regulated IR-induced NO generation and EGFR signal activation.

Inducible liver-specific insulin receptor knockout (iLIRKO) shows insulin resistance in the liver and extrahepatic tissues. Inducible liver-specific insulin.

Curcumin-generated ROS activates Chk1 and Chk2 kinases.

Oligomeric Aβ42 treatment induces expression of Ras and Cyclin D1 and activation of ERK in primary rat cortical neurons. Oligomeric Aβ42 treatment induces.

Recognition of naturally processed HTLV-1 Tax protein derived from HAM patient's PBMC. A, HTLV-1 Tax protein content was evaluated by Western blot analysis.

Variation in dUTPase expression in cell lines.

FOXO3a phosphorylation and expression.

Silencing hOGG1 triggers caspase-3 and caspase-7 activation in response to H2O2 in GM00637 cells. Silencing hOGG1 triggers caspase-3 and caspase-7 activation.

The role of p53 in H2O2-mediated cell death of hOGG1-deficient H1299 lung carcinoma p53 null cells. The role of p53 in H2O2-mediated cell death of hOGG1-deficient.

Identification of NSC as a FADD-kinase inhibitor.

Effect of LY on phosphorylation of various MAP kinase substrates in HeLa cells in vitro. Effect of LY on phosphorylation of various MAP kinase.

Activation of CHOP and DR5 by DIM-C-pPhtBu.

BME treatment increases granzyme B expression in NK 3.3 cells.

CDDO-Me induces apoptosis independent of Bcl-2 level as well as p53 status in human NSCLC cells. CDDO-Me induces apoptosis independent of Bcl-2 level as.

Imatinib mesylate inhibits PDGF-mediated ERK and Akt activation.

Mitotic catastrophe symptoms caused by curcumin are followed by apoptosis. Mitotic catastrophe symptoms caused by curcumin are followed by apoptosis. A.

Geldanamycin-induced endocytosis and down-regulation of ErbB2 in cells expressing ErbB2 only. Geldanamycin-induced endocytosis and down-regulation of ErbB2.

Lamellarin D induces cell death through a Fas-independent pathway.

EGFR and cetuximab sensitivity of SCCUAT

Depletion of HDAC2 sensitizes cells to epirubicin-induced apoptosis.

Greater induction of apoptosis following EGFR TKI treatment correlates with higher basal BIM expression across a panel of EGFR-mutant lung cancers. Greater.

Effects of visfatin on the cell proliferation and phosphorylation of ERK, Akt, and GSK-3β proteins in HCC cells. Effects of visfatin on the cell proliferation.

Effect of G9a on the expression of GSH synthesis enzymes.

Effect of other nucleoside analogues on p38 MAPK phosphorylation levels. Effect of other nucleoside analogues on p38 MAPK phosphorylation levels. A, MM.1S.

MiR-200c is a PI3K–AKT signaling pathway regulator in CRC

Curcumin suppresses the expression of antiapoptotic proteins in multiple myeloma cells. Curcumin suppresses the expression of antiapoptotic proteins in.

HNSCC and NSCLC cell lines display differential sensitivities to cixutumumab in the 3D mimic condition. HNSCC and NSCLC cell lines display differential.

Effect of SFN on the protein expression of Nrf2, HO-1, and NQO1 in JB6-shMock and JB6-shNrf2 cells. Effect of SFN on the protein expression of Nrf2, HO-1,

Dysregulated NF-κB activation in Il1r8+/+/lpr and Il1r8−/−/lpr mice.

Ki-67 expression in M31- and H3-treated tumors (A) and respective Ki-67 labeling indices in the two groups of tumors (B). Ki-67 expression in M31- and.

PKCζ is tyrosine phosphorylated by EGF and contributes to EGF-induced activation of ERK in Mef cells. PKCζ is tyrosine phosphorylated by EGF and contributes.

IGF-II antibodies inhibited IGF-II-induced phosphorylation of IGF-IR and insulin receptor (IR) in the breast cancer MCF-7 cells. IGF-II antibodies inhibited.

PTPH1 depends on its catalytic activity to increase ER nuclear accumulation and to enhance breast cancer sensitivity to TAM. A, effects of PTPH1 and PTPH1/DA.

Immunohistochemical staining for FOXO3a of breast cancer tumor tissues

Met is expressed in Her2-overexpressing cell lines and Her2 (+) breast tumors. Met is expressed in Her2-overexpressing cell lines and Her2 (+) breast tumors.

The Ser124 site of Cdc25A is required for Cdc25A degradation in response to I3C induction. The Ser124 site of Cdc25A is required for Cdc25A degradation.

The combination of trastuzumab and SU11274 abrogate Akt phosphorylation. The combination of trastuzumab and SU11274 abrogate Akt phosphorylation. Serum-starved.

Effects of UVB on AKT in SKH-1 mouse epidermis.

A, effect of Z-VAD treatment on synchronized HeLa MR cells.

SAHA blocks IR-induced increase of RAD51 protein in MM cells.

EGCG affects growth factor receptor signaling in H2111, H358, and H460 NSCLC cells. EGCG affects growth factor receptor signaling in H2111, H358, and H460.

Effect of bevacizumab on the proliferation of A2780 cells.

Expression and induction of HER2 and HPSE in 231BMBC cells.

Posttranslational phosphorylation of p53 by platinum drugs in ovarian tumor cells. Posttranslational phosphorylation of p53 by platinum drugs in ovarian.

Effect of BCAA on the progression of cell cycle, expression of p21CIP1, and induction of apoptosis in HepG2 cells in the presence and absence of visfatin.

LUBAC is essential for NF-κB activity in ABC DLBCL

Elevated STAT3 phosphorylation and RANTES levels in tamoxifen-treated breast cancer cells. Elevated STAT3 phosphorylation and RANTES levels in tamoxifen-treated.

Effect of SFN on the total activity and protein expression of HDACs in JB6 P+ cells. Effect of SFN on the total activity and protein expression of HDACs.

Inhibition of HDACs disrupts DNMT1 association with Hsp90.

I3C reduces the level of Cdc25A protein in breast cancer cells.

Presentation transcript:

Changes in signal transduction pathway induced by gefitinib. Changes in signal transduction pathway induced by gefitinib. A, protein lysates were prepared from breast cancer cells after treatment with 5 μmol/L gefitinib at the time points indicated, and protein expression levels were analyzed by Western blotting using specific antibodies. The Western blot results shown represent the results from a number of attempts, which showed similar trends. Inhibition of phospho-Akt (P-Akt) correlates with inhibition of phospho-FOXO3a (P-FOXO3a) and induction of FOXO3a targets, Bim and p27Kip1 in cells that are sensitive to gefitinib but not in nonsensitive cells. It should be noted that these experiments are designed to follow changes in protein expression during treatment, and because different exposures were used for different cell lines, no comparison between cell lines can be made from these blots. B, quantitative analysis of P-FOXO3a, P-Akt, and P-ERK 1/2 protein expression. Columns, mean results of two independent experiments after normalizing the data to t = 0 h; bars, SD. Statistical analysis has been done using Student's t test. *, P < 0.005; **, P < 0.001; ***, P < 0.05. Janna Krol et al. Mol Cancer Ther 2007;6:3169-3179 ©2007 by American Association for Cancer Research